SLC1A5 is a key regulator of glutamine metabolism and a prognostic marker for aggressive luminal breast cancer
Abstract Cancer cells exhibit altered metabolism, often relying on glutamine (Gln) for growth. Breast cancer (BC) is a heterogeneous disease with varying clinical outcomes. We investigated the role of the amino acid transporter SLC1A5 (ASCT2) and its association with BC subtypes and patient outcomes...
Saved in:
Main Authors: | Lutfi H. Alfarsi, Rokaya El Ansari, Busra Erkan, Ali Fakroun, Madeleine L. Craze, Mohammed A. Aleskandarany, Kiu Wai Cheng, Ian O. Ellis, Emad A. Rakha, Andrew R. Green |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-87292-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma
by: Yan Liao, et al.
Published: (2025-01-01) -
Predictive role of SLC1A5 in neuroblastoma prognosis and immunotherapy
by: Jian Cheng, et al.
Published: (2025-01-01) -
Severe neonatal hypotonia due to SLC30A5 variant affecting function of ZnT5 zinc transporter
by: Vadim Dolgin, et al.
Published: (2025-01-01) -
SLC7A11 is a potential therapeutic target and prognostic biomarker correlated with immune cell infiltration in cervical cancer
by: Mutangala Muloye Guy, et al.
Published: (2025-02-01) -
Comprehensive Pan-Cancer Analysis and Functional Studies Reveal SLC2A6 as a Ferroptosis Modulator in Hepatocellular carcinoma
by: Guohong Yan, et al.
Published: (2025-01-01)